Xilio Therapeutics (NASDAQ:XLO) & Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head Survey

Xilio Therapeutics (NASDAQ:XLO) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Insider & Institutional Ownership

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 7.4% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Xilio Therapeutics and Rigel Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$64.09 million	0.92	-$35.04 million	($1.64)	-5.45
Rigel Pharmaceuticals	$276.79 million	3.03	$367.02 million	$16.32	2.78

Rigel Pharmaceuticals has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Xilio Therapeutics and Rigel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Risk and Volatility

Xilio Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Xilio Therapeutics and Rigel Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1	0	0	0	1.00
Rigel Pharmaceuticals	0	3	4	0	2.57

Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 30.10%. Given Rigel Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Xilio Therapeutics.

Summary

Rigel Pharmaceuticals beats Xilio Therapeutics on 14 of the 14 factors compared between the two stocks.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.